Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04727554 · ClinicalTrials.gov registry record · Phase 1

Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by Amgen.

Completed
Registry status
Phase 1
Development phase
11
Enrollment target
17
Study locations

NCT04727554 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Amgen. The registered enrollment target is 11 participants, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (94% lower). The trial reports 17 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04727554, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Amgen.

COMPLETED
Registry status
Phase 1
Development phase
11 participants
Enrollment target
17
Study locations

Study Summary

The primary objective of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD)/maximum tolerated combination dose (MTCD) or recommended phase 2 dose (RP2D) of AMG 994 as monotherapy and AMG 994 in combination with AMG 404 in participants with advanced solid tumors.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG AMG 994
  • DRUG AMG 404

Study Locations (17)

Other

  • Universitair Ziekenhuis Gent - Ghent
  • Centre Leon Berard - Lyon
  • Universitatsklinikum Ulm - Ulm
  • Universitätsklinikum Würzburg - Würzburg
  • Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy - Warsaw
  • University College London Hospital - London

California

  • City of Hope National Medical Center - Duarte

Michigan

  • Henry Ford Hospital, Henry Ford Health Systems - Detroit

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland

Tennessee

  • Sarah Cannon Research Institute - Nashville

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Victoria

  • Monash Medical Centre - Clayton

Western Australia

  • Linear Clinical Research Limited - Nedlands

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2021-04-29
Est. Completion 2023-06-05
Phase Phase 1

Sponsor

Amgen

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04727554

The ClinicalTrials.gov registry entry for NCT04727554 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (94% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which AMG 994 is the first listed.

NCT04727554 reports 17 study locations spanning 12 distinct geographic areas - top geographies include Other, California, Michigan.

Frequently Asked Questions

What is clinical trial NCT04727554 about?

NCT04727554 is a clinical study titled "Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors". The primary objective of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD)/maximum tolerated combination dose (MTCD) or recommended phase 2 dose (RP2D) of AMG 994 as monotherapy and AMG 994 in combination with AMG 404 in participants with advanced solid tumors.

What is the current status of trial NCT04727554?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2021-04-29. Estimated completion is 2023-06-05.

What conditions does trial NCT04727554 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT04727554?

The interventions under investigation include: AMG 994 (DRUG), AMG 404 (DRUG).

Who is sponsoring clinical trial NCT04727554?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04727554 being conducted?

This trial has 17 study locations across California, Michigan, Ohio, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.